Last year in March, 50-State Network advocate Anna Marie Meyer testified before the Oregon House of Representatives Committee on Health Care in opposition to HB 2026.

HB 254 HD 2 takes positive steps toward updating Hawaii law to cover biologics and biosimilars
in a way that protects patients. As you know, unlike traditional chemical drugs, biologics are
unique, complex structures made from living cells that are not easily replicated. A small change
or difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.

SB 134 takes positive steps toward updating Kentucky law to cover biologics and biosimilars in
a way that protects patients. As you know, unlike traditional chemical drugs, biologics are
unique, complex structures made from living cells that are not easily replicated. A small change
or difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.

SB 313 takes positive steps toward updating Connecticut law to cover biologics and biosimilars
in a way that protects patients.

The committee will discuss biologics license application (BLA) 125544, for CT-P13, a
proposed biosimilar to Janssen Biotech Inc.’s REMICADE (infliximab), submitted by Celltrion,
Inc.

Dr. Califf:

Congratulations on your confirmation by the U.S. Senate to serve as the 22nd Commissioner of the U.S. Food and Drug Administration . You join a distinguished list of public health leaders who have headed one of the federal government’s most important agencies.

Chairman Wood,

The Global Healthy Living Foundation (GHLF) is a 501 (c)(3) patient group that works to
improve the quality of life for people with chronic disease, often focusing on those least able to advocate for themselves.

Good morning Mr. Chairman and committee members.

My name is Rachelle. I’m a patient advocate and member of the Global Healthy Living Foundation’s 50-State Network. I have been a resident of Chesterfield, Michigan for the past 12 years, but I am a lifelong Michigander. My legislators are Representative Andrea LaFontaine and Senator Jack Brandenburg. I want to thank you for allowing me to speak today about House Bill 4812.

The existence of CT-P13, a biosimilar version of infliximab (Remsima), and its recommended approval on Tuesday by the FDA Arthritis Advisory Committee, is reason to celebrate.

Salem resident Joni Johnston testified to the Missouri General Assembly’s House Emerging Issues Committee Jan. 20.